Anjali Singh

Hyundai Motor India has launched Prime HB and Prime SD taxi models with petrol and CNG options, aiming to diversify volumes as domestic competition heats up and rankings tighten

Ducati India says the 40 per cent GST on large-capacity bikes has added pressure on demand and is counting on the proposed India-EU FTA to ease import costs from 2026

Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India

Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India

Triumph will revise ex-showroom prices across its range from January 1, while Renault India will raise prices by up to 2 per cent, urging buyers to lock in current rates

A string of CDSCO approvals and reviews is accelerating India's move to immunotherapies, ADCs and targeted drugs, widening options in major cancers and boosting competition

India's diagnostics sector is seeing a strong shift towards preventive and precision-led testing in 2025, driven by rising demand for proactive health checks and faster genomic diagnostics

Tata Passenger Electric Mobility plans five new EV models by FY30 and Rs 16,000-18,000 crore capex on products, technology and charging infrastructure as Tata EV sales cross 250,000 units

HN Reliance Foundation Hospital has launched a tele-robotic surgery programme, allowing Mumbai surgeons to remotely perform, guide robotic procedures at a Jamnagar partner centre using Jio's network

Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence

As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities

Founded in 2006, Sensa Core operates in the design, development, manufacturing and distribution of specialised in-vitro diagnostic (IVD) devices

Wholesales jump 19 per cent in November even as retail sales soften

Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk

Sun Pharma's Baska plant in Gujarat receives OAI status from the US FDA after inspection, adding near-term regulatory uncertainty but not impacting current US supplies

Scheduled for launch in early 2026, the Gravite will be locally manufactured at Renault-Nissan's Chennai plant and is the first model under Nissan's refreshed India strategy

Tata Motors said the new-generation Sierra logged 70,000 confirmed bookings in 24 hours, with deliveries set from January 15, 2026, and prices ranging from Rs 11.49 lakh

Sales volumes rose 7.2 per cent year-on-year in October 2025 to 19,555 units, before moderating by 1.4 per cent in November to 10,396 units

Planning mid-cycle facelifts over new launches

This optimistic outlook builds on the fact that Swedish companies invested a total of $2.5 bn in India over the last six years, highlighting the expanding economic corridor between the two nations